Skip to main content
Journal cover image

Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment.

Publication ,  Journal Article
Koll, TT; Timperley, J; Ellithi, M; Bhatt, VR; Dai, H; Free, M; Nelson-Sheese, AL; Smith, PJ; Hill, L; Johnson, E; Shelby, RA; Dorfman, CS ...
Published in: J Cancer Surviv
June 20, 2025

PURPOSE: This study examined the pattern of change in cognitive function using the Montreal Cognitive Assessment (MoCA) in the context of physical function and identified risk factors for poor cognitive function post allogeneic HCT in adults ≥ 60 years. MATERIALS AND METHODS: This is a two-center prospective cohort study, measuring cognitive and physical function pre-HCT and 3 months post-HCT. A MoCA score of 26 and above is considered normal. We defined mild impairment as a MoCA score of 23-25, and < 23 as moderate impairment. The Sankey plot was generated to assess the transition of impairment status on the MoCA screen from pre-HCT to 3 months post-HCT. The association of predetermined clinical and demographic variables and 3-month cognitive function and cognitive categories was determined using linear mixed-effects model and ordinal logistic regression, respectively. Predetermined variables including physical function, age, gender, education, depressive symptoms, KPS, HCT-CI, disease type, and treatment intensity were used in multivariate analyses. RESULTS: A total of 171 participants were identified. Pre-HCT, 84 (49%) had normal MoCA scores, 51 (30%) had mild, and 36 (21%) had moderate impairment scores. The prevalence of post-HCT mild impairment scores decreased, and moderate impairment scores nearly doubled. Female gender and pre-HCT functional mobility impairment predicted performance on the MoCA post-HCT above and beyond pre-HCT depressive symptoms, comorbid conditions, KPS, and transplant-related factors. Pre-HCT MoCA and functional mobility scores also predicted post-HCT cognitive categories (normal, mild and moderate impairment). CONCLUSION: Our findings suggest that the pre-HCT MoCA screen can identify those at risk for cognitive impairment post-HCT and can help monitor cognitive function post-HCT. IMPLICATIONS FOR CANCER SURVIVORS: Employing the widely used MoCA threshold for impairment (MoCA < 26) could fail to identify a subgroup requiring intervention and monitoring.

Duke Scholars

Published In

J Cancer Surviv

DOI

EISSN

1932-2267

Publication Date

June 20, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Koll, T. T., Timperley, J., Ellithi, M., Bhatt, V. R., Dai, H., Free, M., … Sung, A. D. (2025). Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment. J Cancer Surviv. https://doi.org/10.1007/s11764-025-01835-z
Koll, Thuy T., Jillian Timperley, Moataz Ellithi, Vijaya R. Bhatt, Hongying Dai, Marcia Free, Amelia L. Nelson-Sheese, et al. “Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment.J Cancer Surviv, June 20, 2025. https://doi.org/10.1007/s11764-025-01835-z.
Koll TT, Timperley J, Ellithi M, Bhatt VR, Dai H, Free M, Nelson-Sheese AL, Smith PJ, Hill L, Johnson E, Shelby RA, Dorfman CS, Zhao AT, Wildes TM, Murman DL, Fisher AL, Sung AD. Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment. J Cancer Surviv. 2025 Jun 20;
Journal cover image

Published In

J Cancer Surviv

DOI

EISSN

1932-2267

Publication Date

June 20, 2025

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis